Pasireotide

Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/[1][2][3].

Product Specifications

CAS Number

[396091-73-9]

Product Name Alternative

SOM230

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/pasireotide.html

Purity

99.94

Solubility

H2O : 45.45 mg/mL (adjust pH to 1 with 1 M HCl)

Smiles

NCCCC[C@@H](C(N[C@H]1CC2=CC=C(C=C2)OCC3=CC=CC=C3)=O)NC([C@H](NC([C@H](C4=CC=CC=C4)NC([C@H]5N(C([C@H](CC6=CC=CC=C6)NC1=O)=O)C[C@H](OC(NCCN)=O)C5)=O)=O)CC7=CNC8=C7C=CC=C8)=O

Molecular Formula

C58H66N10O9

Molecular Weight

1047.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46 (12) :2334-44.|[2]Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152 (6) :1068-77.|[3]Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63 (8) :2352-62.|[4]Schmid HA, et, al. Pasireotide (SOM230) : development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008 May 14;286 (1-2) :69-74.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

Launched

Citation 01

Basic Clin Pharmacol Toxicol. 2022 Sep;131 (3) :174-188.|J Clin Invest. 2024 October 1.|Am J Pathol. 2018 Apr;188 (4) :981-994.|Commun Med (Lond) . 2022 Jul 1:2:80.|Hepatology. 2017 Oct;66 (4) :1197-1218.|Universidad De Salamanca. Biología y Clínica del Cáncer y Medicina Traslacional. 2022 Oct.